CN101557823A - 人内源性逆转录病毒多肽组合物和其使用方法 - Google Patents

人内源性逆转录病毒多肽组合物和其使用方法 Download PDF

Info

Publication number
CN101557823A
CN101557823A CNA2007800276077A CN200780027607A CN101557823A CN 101557823 A CN101557823 A CN 101557823A CN A2007800276077 A CNA2007800276077 A CN A2007800276077A CN 200780027607 A CN200780027607 A CN 200780027607A CN 101557823 A CN101557823 A CN 101557823A
Authority
CN
China
Prior art keywords
herv
cells
leu
polypeptide
immunogenic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800276077A
Other languages
English (en)
Chinese (zh)
Inventor
马里奥·奥斯特洛夫斯基
布拉德利·R·琼斯
塞斯·雷克夫-纳乌姆
D·尼克松
K·加里森
D·梅克勒约翰
A·阿格拉沃尔
J·伦茨
F·M·赫克特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Einstein Medical Department
J David Gladstone Institutes
University of California San Diego UCSD
Original Assignee
Albert Einstein Medical Department
J David Gladstone Institutes
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein Medical Department, J David Gladstone Institutes, University of California San Diego UCSD filed Critical Albert Einstein Medical Department
Publication of CN101557823A publication Critical patent/CN101557823A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CNA2007800276077A 2006-07-21 2007-07-19 人内源性逆转录病毒多肽组合物和其使用方法 Pending CN101557823A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83246506P 2006-07-21 2006-07-21
US60/832,465 2006-07-21

Publications (1)

Publication Number Publication Date
CN101557823A true CN101557823A (zh) 2009-10-14

Family

ID=38957380

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800276077A Pending CN101557823A (zh) 2006-07-21 2007-07-19 人内源性逆转录病毒多肽组合物和其使用方法

Country Status (15)

Country Link
US (2) US20080171061A1 (https=)
EP (1) EP2046380A4 (https=)
JP (1) JP2009544614A (https=)
KR (1) KR20090060410A (https=)
CN (1) CN101557823A (https=)
AU (1) AU2007275693A1 (https=)
BR (1) BRPI0714714A2 (https=)
CA (1) CA2658393A1 (https=)
IL (1) IL196516A0 (https=)
MX (1) MX2009000659A (https=)
NO (1) NO20090818L (https=)
RU (1) RU2009106089A (https=)
SG (1) SG173997A1 (https=)
WO (1) WO2008011120A2 (https=)
ZA (1) ZA200900379B (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109415429A (zh) * 2016-06-30 2019-03-01 美国政府(由卫生和人类服务部的部长所代表) Herv-e反应性t细胞受体及使用方法
CN109863165A (zh) * 2016-08-23 2019-06-07 爱姆维恩公司 新型免疫刺激肽
CN111093691A (zh) * 2017-04-03 2020-05-01 内恩疗法公司 蛋白质抗原及其用途
CN111630060A (zh) * 2017-09-01 2020-09-04 盈珀治疗有限公司 用于在疾病的预防和/或治疗中使用的疫苗
CN112867502A (zh) * 2018-09-06 2021-05-28 里昂贝拉尔德中心 Herv-k衍生抗原作为共有肿瘤抗原用于抗癌疫苗

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8398983B2 (en) 2005-06-27 2013-03-19 Glaxosmithkline Biologicals, S.A. Immunogenic composition
US20090297530A1 (en) 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
EP2340851A4 (en) * 2008-09-18 2012-09-26 Univ Keio DIAGNOSTIC METHOD AND THERAPEUTIC METHOD FOR CANCER
WO2010053772A2 (en) 2008-10-29 2010-05-14 The Regents Of The University Of California Disease-associated antigens and methods of use thereof
EP2519539A4 (en) * 2009-12-28 2013-11-13 Ligocyte Pharmaceuticals Inc METHODS FOR STABILIZING VIRUS-LIKE PARTICULATE SOLUTIONS BASED ON INFLUENZA-INFLUENZA-VIRUSED VIRUSES
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
WO2013112951A2 (en) 2012-01-26 2013-08-01 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
WO2014153114A1 (en) * 2013-03-14 2014-09-25 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
JP7348063B2 (ja) 2017-01-05 2023-09-20 フレッド ハッチンソン キャンサー センター ワクチン効力を改善するためのシステム及び方法
US11793867B2 (en) 2017-12-18 2023-10-24 Biontech Us Inc. Neoantigens and uses thereof
CN111629715A (zh) 2018-01-18 2020-09-04 弗莱德哈钦森癌症研究中心 通过调节细胞活化状态改变体内免疫细胞的炎症状态
BR112020025764A2 (pt) 2018-06-19 2021-05-11 Biontech Us Inc. neoantígenos e usos dos mesmos
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
EP4185600A4 (en) 2020-07-24 2024-12-04 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
US20240189247A1 (en) * 2022-11-16 2024-06-13 The General Hospital Corporation Minimal Human-Derived Virus-Like Particles and Methods of Use Thereof for Delivery of Biomolecules
US20260035415A1 (en) * 2024-08-01 2026-02-05 Twilight Bioscience, Inc. Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
US20030162263A1 (en) * 2001-09-06 2003-08-28 Marc Dupuis Peptides derived from the superantigen (SAg) ENV protein of HERV-K18 and their use in obtaining SAG-inhibitory antibodies and in vaccination against SAG
AT411262B (de) * 2001-09-27 2003-11-25 Wolff Klaus Dr Humanes endogenes retrovirus
WO2003050258A2 (en) * 2001-12-07 2003-06-19 Chiron Corporation Endogenous retrovirus polypeptides linked to oncogenic transformation
US20040096457A1 (en) * 2001-12-11 2004-05-20 Huber Brigitte T Treatment and prevention of ebv infection and ebv-associated disorders
EP1338606A1 (en) * 2002-02-22 2003-08-27 Magnus Von Knebel Doeberitz Nucleic Acid encoding an HERV-H polypeptide for diagnosing colorectal cancer
EP2516459A1 (en) * 2009-12-22 2012-10-31 Aarhus Universitet (University Of Aarhus) Bivalent molecules for hiv entry inhibition
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109415429A (zh) * 2016-06-30 2019-03-01 美国政府(由卫生和人类服务部的部长所代表) Herv-e反应性t细胞受体及使用方法
CN109415429B (zh) * 2016-06-30 2023-04-28 美国政府(由卫生和人类服务部的部长所代表) Herv-e反应性t细胞受体及使用方法
US11779603B2 (en) 2016-06-30 2023-10-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HERV-E reactive T cell receptors and methods of use
CN109863165A (zh) * 2016-08-23 2019-06-07 爱姆维恩公司 新型免疫刺激肽
CN111093691A (zh) * 2017-04-03 2020-05-01 内恩疗法公司 蛋白质抗原及其用途
CN111630060A (zh) * 2017-09-01 2020-09-04 盈珀治疗有限公司 用于在疾病的预防和/或治疗中使用的疫苗
CN111630060B (zh) * 2017-09-01 2024-01-23 盈珀治疗有限公司 用于在疾病的预防和/或治疗中使用的疫苗
CN112867502A (zh) * 2018-09-06 2021-05-28 里昂贝拉尔德中心 Herv-k衍生抗原作为共有肿瘤抗原用于抗癌疫苗

Also Published As

Publication number Publication date
BRPI0714714A2 (pt) 2013-04-09
JP2009544614A (ja) 2009-12-17
MX2009000659A (es) 2009-06-08
IL196516A0 (en) 2011-08-01
AU2007275693A1 (en) 2008-01-24
US20130323279A1 (en) 2013-12-05
ZA200900379B (en) 2010-08-25
EP2046380A2 (en) 2009-04-15
US20080171061A1 (en) 2008-07-17
RU2009106089A (ru) 2010-08-27
SG173997A1 (en) 2011-09-29
WO2008011120A2 (en) 2008-01-24
KR20090060410A (ko) 2009-06-12
EP2046380A4 (en) 2013-05-01
NO20090818L (no) 2009-04-17
CA2658393A1 (en) 2008-01-24
WO2008011120A3 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
CN101557823A (zh) 人内源性逆转录病毒多肽组合物和其使用方法
CN101969987A (zh) 长散布核元件多肽组合物及其使用方法
RU2682726C9 (ru) Вакцинная композиция против злокачественной опухоли
US11660335B2 (en) Vaccines against coronavirus and methods of use
JP6143781B2 (ja) エンベロープウイルスにより引き起こされる疾病を治療するための方法および組成物
JPH03503166A (ja) 抗ｈｉｖ応答を喚起する合成抗原
US9486518B2 (en) Membrane proximal region of HIV GP41 anchored to the lipid layer of a virus-like particle vaccine
US9572873B2 (en) Method of inducing a T lymphocyte response using T-cell immunogens derived from anti-viral proteins
JP2022501046A (ja) アルギナーゼ１ポリペプチド
WO2016184962A1 (en) Treatment of hiv-infected individuals
JP2005526729A (ja) レトロウイルス免疫療法の戦略
WO2022236301A1 (en) Vaccines against coronavirus and methods of use
HK1135023A (en) Human endogenous retrovirus polypeptide compositions and methods of use thereof
WO2025117490A1 (en) Arenavirus t cell epitopes, megapools and uses thereof
JP2026512959A (ja) 抗ｐｄ－１抗体又は抗ｐｄ－ｌ１抗体を用いたがん治療法
WO2022125610A1 (en) Perforin inhibitors and uses thereof
Berzofsky Human Immunodeficiency Virus: Structural Features of T-Cell
JP2010001303A (ja) Ｈｌａ結合ペプチド及びその使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1135023

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20091014

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1135023

Country of ref document: HK